Primary Biliary Cholangitis (PBC)

1. Clinical Overview

Summary

Primary Biliary Cholangitis (PBC), formerly known as Primary Biliary Cirrhosis, is a chronic progressive autoimmune liver disease characterised by immune-mediated destruction of the small intrahepatic bile ducts, leading to cholestasis, progressive hepatic fibrosis, and ultimately cirrhosis if untreated. [1,2]

The disease predominantly affects middle-aged women (female to male ratio 9:1), with peak diagnosis between ages 40-60 years. The pathognomonic serological feature is the presence of anti-mitochondrial antibodies (AMA), specifically directed against the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), detected in approximately 90-95% of patients. [1,3]

Clinical presentation ranges from asymptomatic elevation of alkaline phosphatase (ALP) detected on routine biochemistry to symptomatic disease characterised by fatigue and pruritus. In advanced stages, patients may develop features of decompensated cirrhosis including jaundice, ascites, hepatic encephalopathy, and variceal haemorrhage. [2,4]

Ursodeoxycholic acid (UDCA) at a dose of 13-15 mg/kg/day remains the first-line therapy and improves biochemical parameters, delays histological progression, and enhances transplant-free survival in the majority of patients. Second-line therapies including obeticholic acid, bezafibrate, and more recently seladelpar are reserved for incomplete responders to UDCA. Liver transplantation offers excellent outcomes for patients with decompensated disease or intractable symptoms. [1,2,5]

Key Statistics

Clinical Pearls

AMA is the Pathognomonic Antibody: Anti-Mitochondrial Antibody (AMA), specifically AMA-M2 directed against PDC-E2, is present in 90-95% of PBC patients and has a specificity exceeding 95%. The combination of AMA positivity with cholestatic liver biochemistry is virtually diagnostic. [3]

Disease Renamed in 2014: The terminology changed from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis" because many patients are now diagnosed at early stages before cirrhosis develops, and the name "cirrhosis" was psychologically distressing to patients. [9]

Pruritus Can Be Devastating: Cholestatic pruritus in PBC can be profoundly debilitating, interfering with sleep, work, and quality of life. It is often the presenting symptom and may precede biochemical abnormalities. In rare cases, intractable pruritus alone is an indication for liver transplantation. [10]

UDCA is Universal First-Line Therapy: All patients with confirmed PBC should receive ursodeoxycholic acid (13-15 mg/kg/day) unless there are specific contraindications. UDCA improves biochemistry, delays histological progression, and improves transplant-free survival. [1,2]

Beware the Overlap Syndrome: Approximately 5-10% of patients have features of both PBC and autoimmune hepatitis (AIH), termed PBC-AIH overlap syndrome. These patients may require combined therapy with UDCA and immunosuppression. [11]

ALP is the Sentinel Marker: Serum alkaline phosphatase is the most sensitive biochemical marker for PBC. Persistently elevated ALP in a middle-aged woman should prompt AMA testing and consideration of PBC. [1]

---

2. Epidemiology

Global Prevalence and Incidence

PBC is a relatively uncommon condition with significant geographical variation. The highest prevalence is reported in Northern Europe and North America, with lower rates in Asia and Africa. This variation likely reflects both genetic susceptibility and environmental factors, as well as differences in diagnostic practices. [6]

The incidence of PBC appears to be increasing over the past three decades, likely due to improved awareness, increased serological testing (widespread use of AMA testing), and earlier detection through incidental finding of elevated ALP on routine biochemistry. [6]

Demographics

Gender Distribution

PBC demonstrates a profound female predominance with a female-to-male ratio of approximately 9:1. This striking gender disparity suggests a role for sex hormones, X-chromosome genes, or gender-specific environmental exposures in disease pathogenesis. [1,2]

Age at Diagnosis

• Peak age: 40-60 years
• Median age at diagnosis: 55 years
• Age range: Can occur from 20s to 90s, but diagnosis before age 30 or after age 80 is uncommon
• Presentation: Younger patients may have more aggressive disease; older patients often have asymptomatic disease detected incidentally [2]

Risk Factors and Associations

Genetic Susceptibility

• Familial clustering: First-degree relatives of PBC patients have a significantly elevated risk (prevalence 1-6% in family members vs. 0.03% in general population)
• Concordance in twins: Monozygotic twins show 63% concordance vs. 0% in dizygotic twins
• HLA associations: HLA-DRB108, DRB10301, and DRB1*1104 confer increased susceptibility [12]
• Non-HLA genes: Multiple genome-wide association studies (GWAS) have identified susceptibility loci including IL12A, IL12RB2, STAT4, IRF5-TNPO3, 17q12-21, and MMEL1 [12]

Environmental Factors

Epidemiological studies suggest potential environmental triggers:

• Infections: Possible molecular mimicry with bacterial PDC-E2 homologues (Escherichia coli, Novosphingobium aromaticivorans)
• Smoking: Associated with increased PBC risk and disease progression
• Recurrent urinary tract infections: Reported in some case-control studies
• Nail polish/cosmetics: Xenobiotic exposure suggested in some studies but not consistently replicated [12]

Associated Autoimmune Conditions

PBC frequently coexists with other autoimmune diseases, supporting a shared autoimmune diathesis. The prevalence of at least one additional autoimmune condition ranges from 50-84% of PBC patients. [7]

---

3. Pathophysiology

Molecular and Cellular Mechanisms

PBC is an organ-specific autoimmune disease targeting the intrahepatic small bile ducts. The pathogenesis involves a complex interplay of genetic susceptibility, environmental triggers, loss of immune tolerance, and bile duct-specific immune attack. [12,13]

Exam Detail: Step 1: Loss of Immunological Tolerance

The central event in PBC pathogenesis is the breakdown of immune tolerance to the mitochondrial pyruvate dehydrogenase complex E2 subunit (PDC-E2), a ubiquitous mitochondrial enzyme. Why this tolerance is lost specifically in biliary epithelial cells remains incompletely understood. [13]

Proposed mechanisms include:

1. Molecular mimicry: Microbial PDC-E2 homologues (e.g., from E. coli or Novosphingobium aromaticivorans) may trigger cross-reactive immune responses
2. Xenobiotic modification: Environmental chemicals may modify self-antigens, creating neo-antigens
3. Apotope formation: Unique presentation of PDC-E2 during biliary epithelial cell apoptosis may break tolerance
4. Genetic predisposition: HLA and non-HLA susceptibility genes impair central and peripheral tolerance mechanisms

Step 2: Biliary Epithelial Cell Targeting

Despite PDC-E2 being ubiquitously expressed in mitochondria of all cells, the immune attack is specifically directed at small intrahepatic bile ducts. Several unique features of cholangiocytes explain this:

1. Aberrant PDC-E2 expression: Cholangiocytes (unlike other cells) express immunologically intact PDC-E2 on their apical surface and within apoptotic blebs [13]
2. Enhanced apoptosis: Biliary epithelial cells in PBC undergo increased apoptosis, with glutathionylated PDC-E2 remaining immunologically intact in apoptotic blebs
3. Cholangiocyte senescence: Biliary epithelial cells develop a senescence-associated secretory phenotype (SASP), releasing pro-inflammatory cytokines
4. Bile acid toxicity: Hydrophobic bile acids retained due to cholestasis further damage cholangiocytes

Step 3: Adaptive Immune Response

B-cell Response:

• Anti-mitochondrial antibodies (AMA) are directed primarily against PDC-E2 (and also against other 2-oxo-acid dehydrogenase complex components including BCOADC-E2 and OGDC-E2)
• AMAs are detectable in serum (often years before symptom onset) and persist throughout the disease course
• While AMAs are highly specific for diagnosis, their direct pathogenic role remains uncertain; disease severity does not correlate with AMA titres, and AMA-negative PBC exists [3,13]

T-cell Response:

• CD4+ T-helper cells (Th1 and Th17 subsets) infiltrate portal tracts and surround damaged bile ducts
• CD8+ cytotoxic T-lymphocytes are the predominant effector cells causing bile duct destruction
• Autoreactive T-cells specific for PDC-E2 are found in liver, lymph nodes, and peripheral blood
• Regulatory T-cell (Treg) dysfunction: Impaired Treg function fails to suppress autoreactive T-cells [13]

Step 4: Innate Immune Activation

• Cholangiocytes express aberrant MHC Class II molecules, allowing direct antigen presentation to CD4+ T-cells
• Toll-like receptor (TLR) signaling: Cholangiocytes express TLRs and respond to microbial products, amplifying inflammation
• Natural killer (NK) cells and natural killer T (NKT) cells contribute to early bile duct injury
• Macrophages and dendritic cells infiltrate portal areas and release pro-inflammatory cytokines (TNF-α, IL-12, IFN-γ) [13]

Step 5: Bile Duct Destruction and Ductopenia

• Granulomatous inflammation surrounds small bile ducts (the "florid duct lesion" pathognomonic of PBC)
• Progressive ductopenia: Bile ducts disappear due to immune-mediated destruction
• Bile ductular proliferation: Attempted regeneration produces tortuous, poorly functional ductules
• Chronic cholestasis: Loss of functional bile ducts impairs bile secretion and flow [2,13]

Step 6: Hepatocyte Injury and Fibrosis

• Toxic bile acid accumulation: Reduced bile flow leads to retention of hydrophobic bile acids (chenodeoxycholic acid, deoxycholic acid) which are hepatotoxic
• Hepatocyte apoptosis and necrosis: Toxic bile acids activate death receptors and mitochondrial apoptosis pathways
• Hepatic stellate cell activation: Chronic inflammation and hepatocyte injury activate stellate cells, which differentiate into myofibroblasts producing collagen
• Progressive fibrosis: Initially periportal (stage II), then bridging fibrosis (stage III), culminating in cirrhosis (stage IV) [2]

Step 7: Cirrhosis and Decompensation

• Portal hypertension: Architectural distortion and increased intrahepatic resistance
• Hepatocellular dysfunction: Loss of functional hepatocyte mass impairs synthetic, metabolic, and detoxification functions
• Decompensation: Ascites, variceal haemorrhage, hepatic encephalopathy, hepatorenal syndrome
• Hepatocellular carcinoma: Cirrhotic PBC carries an increased HCC risk, though lower than viral hepatitis-related cirrhosis [2]

Histological Stages (Ludwig/Scheuer Classification)

Liver histology in PBC progresses through four stages, though progression is not necessarily linear and different areas of the liver may show different stages. [2]

The Florid Duct Lesion

The florid duct lesion is the histological hallmark of PBC, though it is present in only 50-60% of biopsies (it is patchy and may be missed on needle biopsy). It consists of:

• Granulomatous inflammation surrounding and infiltrating small interlobular bile ducts
• Non-caseating epithelioid granulomas (similar to sarcoidosis)
• Lymphocytic infiltration of the bile duct epithelium
• Bile duct degeneration and eventual destruction

---

4. Differential Diagnosis

PBC must be distinguished from other causes of cholestatic liver disease and other autoimmune liver diseases.

Cholestatic Liver Disease Differential

Key Differentiating Features

PBC vs. PSC:

• Serology: AMA positive in PBC; AMA negative, p-ANCA often positive in PSC
• Imaging: Normal intrahepatic and extrahepatic bile ducts in PBC; beaded/strictured ducts on MRCP in PSC
• Associations: PBC associated with Sjögren's, thyroid disease; PSC associated with inflammatory bowel disease (70%, particularly ulcerative colitis)
• Demographics: PBC predominantly middle-aged women; PSC predominantly younger men

PBC vs. AIH:

• LFT pattern: Cholestatic (ALP predominance) in PBC; hepatitic (AST/ALT predominance) in AIH
• Serology: AMA in PBC; ANA, ASMA, anti-LKM in AIH
• Immunoglobulins: Elevated IgM in PBC; elevated IgG in AIH
• Histology: Bile duct destruction in PBC; interface hepatitis and plasma cell infiltration in AIH

PBC-AIH Overlap Syndrome:

Approximately 5-10% of patients have features of both PBC and AIH. Diagnosis requires meeting criteria for both conditions (the "Paris criteria"): [11]

PBC criteria (≥2 of):

1. ALP ≥2× ULN or GGT ≥5× ULN
2. AMA positive
3. Liver biopsy with florid duct lesion

AIH criteria (≥2 of):

1. ALT ≥5× ULN
2. IgG ≥2× ULN or ASMA positive
3. Liver biopsy with moderate/severe interface hepatitis

Management: Overlap syndrome requires combination therapy with UDCA plus immunosuppression (corticosteroids ± azathioprine). [11]

---

5. Clinical Presentation

Spectrum of Presentation

PBC presents across a wide spectrum, from asymptomatic biochemical abnormalities to advanced cirrhosis with decompensation. The clinical presentation has evolved over recent decades due to earlier detection through routine biochemical screening. [2,4]

The asymptomatic proportion has increased from approximately 25% in the 1980s to 50-60% currently, reflecting increased awareness and widespread use of automated biochemical panels. [4]

Symptoms

Signs

Physical examination may be entirely normal in early, asymptomatic PBC. As disease progresses, the following signs may develop:

Associated Conditions and Extrahepatic Manifestations

---

6. Investigations

Diagnostic Algorithm

Exam Detail: Diagnosis of PBC is typically straightforward and based on a combination of biochemical cholestasis, serological evidence of AMA positivity, and exclusion of biliary obstruction. Liver biopsy is not routinely required if the first two criteria are met. [1,2]

Biochemistry

Serology

AMA-Negative PBC:

Approximately 5-10% of patients have clinical, biochemical, and histological features of PBC but are AMA-negative. These patients often have PBC-specific ANAs (anti-sp100, anti-gp210) and are now recognized as having "AMA-negative PBC" rather than a separate entity. They respond to UDCA similarly to AMA-positive patients. [3,14]

Imaging

Liver Biopsy

Indications (liver biopsy is not routinely required if AMA positive + cholestatic LFTs): [1,2]

1. AMA-negative cholestasis (to confirm diagnosis)
2. Suspicion of PBC-AIH overlap syndrome (mixed biochemical pattern, elevated IgG, positive ASMA/ANA)
3. Atypical features (e.g., young male, absence of autoimmune associations)
4. Staging (to assess degree of fibrosis, though non-invasive methods increasingly used)
5. Research or clinical trial enrollment

Histological Features:

Limitations:

• Patchy disease: Florid duct lesion may be missed on needle biopsy
• Sampling variability: Different areas may show different stages
• Risk: Small risk of bleeding, pain, pneumothorax

Diagnostic Criteria

EASL/AASLD Diagnostic Criteria for PBC: [1,2]

Diagnosis established if ≥2 of the following 3 criteria are met:

1. Biochemical cholestasis: Elevated ALP (≥1.5× ULN) for ≥6 months
2. Positive AMA (titre ≥1:40) or PBC-specific ANA (anti-sp100, anti-gp210)
3. Liver biopsy consistent with PBC (if performed)

In the majority of cases, diagnosis is made on criteria 1 + 2 without liver biopsy.

---

7. Management

Management Principles

The goals of PBC management are:

1. Slow disease progression and prevent or delay cirrhosis
2. Improve transplant-free survival
3. Manage symptoms (fatigue, pruritus)
4. Prevent and manage complications (osteoporosis, vitamin deficiency, cirrhosis complications)
5. Screen for and manage associated autoimmune conditions
6. Liver transplantation in decompensated disease or intractable symptoms

Management Algorithm

                    SUSPECTED PBC
   (Middle-Aged Woman, Elevated ALP, Fatigue/Pruritus)
                         ↓
    CHECK: AMA, LFTs, Liver USS (exclude biliary obstruction)
                         ↓
           ┌─────────────┴─────────────┐
    AMA +ve + Cholestatic LFTs     AMA -ve + Cholestatic LFTs
           ↓                              ↓
    DIAGNOSIS: PBC               CONSIDER:
    (No biopsy needed)           • Check PBC-specific ANA (anti-sp100, anti-gp210)
                                 • MRCP (exclude PSC)
                                 • Liver biopsy
                                 • If features of AIH: consider overlap syndrome
                         ↓
                  CONFIRMED PBC
                         ↓
              ┌──────────┴──────────┐
          Bilirubin Normal      Bilirubin Elevated
              ↓                      ↓
    START URSODEOXYCHOLIC ACID   Consider transplant evaluation
    (UDCA) 13-15 mg/kg/day       + Start UDCA
              ↓
    ASSESS RESPONSE AT 12 MONTHS
    (Paris-2 Criteria: ALP less than 1.5× ULN, AST less than 1.5× ULN, Bilirubin normal)
              ↓
    ┌─────────┴─────────┐
ADEQUATE RESPONSE    INADEQUATE RESPONSE
    ↓                    ↓
Continue UDCA        ADD SECOND-LINE THERAPY:
Monitor annually     • Obeticholic Acid (OCA) 5-10 mg daily
• LFTs                 (if no decompensated cirrhosis)
• Fibroscan          • OR Bezafibrate (off-label, Europe)
• HCC surveillance   • OR Seladelpar (emerging therapy)
  (if cirrhotic)       ↓
                   Reassess at 12 months
                       ↓
                   If still inadequate or
                   decompensated cirrhosis:
                   LIVER TRANSPLANT EVALUATION
                         ↓
              SYMPTOM MANAGEMENT (All Patients):
              • Pruritus: Cholestyramine → Rifampicin → Naltrexone
              • Fatigue: Exclude other causes, supportive measures
              • Osteoporosis: DEXA scan, Calcium + Vitamin D, Bisphosphonates
              • Fat-soluble vitamin deficiency: Supplement A, D, E, K
              • Screen and manage associated autoimmune conditions

First-Line Therapy: Ursodeoxycholic Acid (UDCA)

UDCA is the cornerstone of PBC therapy and should be initiated in all patients with confirmed PBC unless there are specific contraindications. [1,2,5]

Biochemical Response Criteria:

Several criteria exist to define "adequate response" to UDCA. Patients meeting response criteria have significantly better transplant-free survival. [8]

Approximately 30-40% of patients are incomplete responders to UDCA and require second-line therapies. [5]

Second-Line Therapies (for UDCA Incomplete Responders)

EASL/AASLD Recommendations: [1,2]

• Add second-line therapy if inadequate response to UDCA at 12 months
• Obeticholic acid is the only licensed second-line agent (add to UDCA)
• Bezafibrate is an alternative, particularly in Europe (off-label)
• Seladelpar is an emerging option with recent approval
• Continue UDCA when adding second-line therapy (synergistic benefit)

Management of Pruritus

Pruritus is one of the most debilitating symptoms of PBC and requires a stepwise approach. [10]

Stepwise Approach:

1. Start cholestyramine (separate from UDCA)
2. If ineffective/not tolerated, switch to rifampicin (monitor LFTs closely)
3. If still inadequate, add naltrexone or sertraline
4. Consider bezafibrate as second-line PBC therapy with pruritus benefit
5. Refractory cases: refer to specialist center for plasmapheresis/MARS or transplant evaluation

Symptomatic Measures:

• Cool environment (avoid overheating)
• Emollients and moisturizers
• Avoid irritant fabrics
• Short nails (reduce excoriation)
• Antihistamines (usually ineffective for cholestatic itch but may aid sleep)

Management of Fatigue

Fatigue is the most common symptom in PBC but unfortunately has no proven specific treatment. Management is supportive and focused on excluding other causes. [10]

Important: UDCA does not improve fatigue. Fatigue severity does not correlate with biochemical response.

Management of Associated Conditions and Complications

Liver Transplantation

Liver transplantation is the definitive treatment for decompensated PBC and offers excellent outcomes. [19]

Monitoring and Follow-Up

---

8. Complications

---

9. Prognosis and Outcomes

Natural History

The natural history of PBC has dramatically improved with the introduction of UDCA and earlier diagnosis. [8,15]

Prognostic Factors

Bilirubin is the single most important prognostic marker. Rising bilirubin despite UDCA therapy mandates transplant evaluation. [8]

Prognostic Models

Several models predict outcomes in PBC:

These models help identify high-risk patients who may benefit from more intensive monitoring or second-line therapy.

Transplantation Outcomes

PBC is one of the most successful indications for liver transplantation.

---

10. Prevention and Screening

Primary Prevention

There are no established primary prevention strategies for PBC, as the etiology and environmental triggers remain incompletely understood.

General recommendations:

• Avoid smoking (associated with disease progression)
• No specific dietary or lifestyle modifications proven to prevent PBC

Screening

Family Members:

• First-degree relatives of PBC patients have increased risk (1-6% prevalence vs. 0.03% general population)
• Consider screening with AMA and LFTs if:
  • Symptoms (fatigue, pruritus)
  • Incidental elevated ALP
  • Family history of autoimmune disease

General Population:

• No population-based screening recommended
• Opportunistic screening in middle-aged women with unexplained elevated ALP

Patients with Other Autoimmune Diseases:

• Consider screening with AMA and LFTs in patients with:
  • Sjögren's syndrome
  • Systemic sclerosis
  • Autoimmune thyroid disease
  • Rheumatoid arthritis

---

11. Evidence and Guidelines

Key Guidelines

Landmark Studies and Evidence

---

12. Patient and Layperson Explanation

What is Primary Biliary Cholangitis (PBC)?

Primary Biliary Cholangitis (PBC) is a long-term (chronic) liver condition where your body's immune system mistakenly attacks the small tubes (bile ducts) inside your liver. These bile ducts normally carry a digestive fluid called bile from your liver to your intestines to help digest fats.

When the bile ducts are damaged, bile cannot flow properly and builds up in the liver, causing inflammation and, over time, scarring (fibrosis). If left untreated, this can eventually lead to cirrhosis (severe scarring) of the liver.

Why did I develop PBC?

We don't fully understand why PBC develops. It is an autoimmune disease, meaning your immune system attacks your own body by mistake. It is not caused by alcohol, infections, or anything you did wrong.

Some factors that may play a role include:

• Genetics: It can run in families, though it is not directly inherited
• Environmental triggers: Possible infections or chemical exposures may trigger the condition in people who are genetically susceptible
• Female hormones: PBC is much more common in women (9 out of 10 people with PBC are women), suggesting hormones may play a role

What are the symptoms?

Many people with PBC have no symptoms at first and are diagnosed when blood tests show abnormal liver enzymes during routine check-ups.

When symptoms do occur, the most common are:

• Fatigue (tiredness): Often severe and not relieved by rest
• Itching (pruritus): Can be intense, especially at night
• Dry eyes and dry mouth: Due to an associated condition called Sjögren's syndrome
• Yellowing of the skin or eyes (jaundice): A late symptom indicating more advanced disease

How is PBC diagnosed?

Your doctor will diagnose PBC using:

1. Blood tests: Looking for a specific antibody called anti-mitochondrial antibody (AMA), which is present in 9 out of 10 people with PBC
2. Liver function tests: Showing elevated alkaline phosphatase (ALP), a marker of bile duct problems
3. Ultrasound scan: To make sure there is no blockage of the bile ducts
4. Liver biopsy (sometimes): A small sample of liver tissue examined under a microscope, though this is not always needed

What is the treatment?

The main treatment is a medication called Ursodeoxycholic Acid (UDCA). This is a bile acid that:

• Helps bile flow through the liver
• Protects liver cells from damage
• Slows down the progression of the disease
• Improves long-term survival

You should take UDCA every day as prescribed. Most people respond well to UDCA and can live a normal or near-normal lifespan.

If UDCA does not work well enough, your doctor may add a second medication such as:

• Obeticholic acid
• Bezafibrate
• Seladelpar

What about the itching?

Itching can be very troublesome. Treatments include:

• Cholestyramine: A powder that binds bile acids in your intestines
• Rifampicin: An antibiotic that can help reduce itching
• Other medications: Such as naltrexone or sertraline

Your doctor will work with you to find the best treatment for your itching.

What about the tiredness?

Unfortunately, there is no specific treatment for the fatigue associated with PBC. Your doctor will:

• Check for other causes of tiredness (such as thyroid problems, anaemia, or poor sleep)
• Recommend pacing yourself and gentle exercise
• Provide support and understanding

Will I need a liver transplant?

Most people with PBC who respond well to UDCA will not need a liver transplant and can live a normal lifespan.

A liver transplant is only needed if:

• The disease progresses to severe cirrhosis despite treatment
• You develop complications such as liver failure
• Rarely, if itching is so severe that it cannot be controlled with medications

Liver transplant outcomes for PBC are excellent, with over 90% of people alive and well 5 years after transplant.

What else should I know?

• PBC is not contagious: You cannot pass it to others
• It is not caused by alcohol: You do not need to feel guilty or blame yourself
• Regular monitoring is important: Blood tests and check-ups help your doctor assess how well the treatment is working
• You may have other autoimmune conditions: Such as thyroid problems or Sjögren's syndrome. Your doctor will screen for these.
• Lifestyle: Avoid smoking, maintain a healthy weight, and eat a balanced diet. Avoid excessive alcohol.

What is my outlook?

With early diagnosis and treatment with UDCA, most people with PBC have a good outlook and can expect a normal or near-normal lifespan. Regular monitoring and treatment are key.

If you have any questions or concerns, please speak to your doctor or liver specialist.

---

13. Examination Focus

High-Yield Facts for Exams

Common Viva Questions and Model Answers

Exam Detail: Q1: What is the pathognomonic antibody in PBC, and what is its target antigen?

Model Answer: The pathognomonic antibody in PBC is the anti-mitochondrial antibody (AMA), specifically the AMA-M2 subtype. It is directed against the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), a mitochondrial enzyme involved in the Krebs cycle. AMA is present in approximately 90-95% of PBC patients and has a specificity exceeding 95%, making it highly specific for PBC. The combination of AMA positivity with cholestatic liver biochemistry (elevated ALP) is virtually diagnostic of PBC.

Q2: Describe the diagnostic criteria for PBC.

Model Answer: The diagnosis of PBC is established if ≥2 of the following 3 criteria are met (EASL/AASLD criteria):

1. Biochemical cholestasis: Elevated alkaline phosphatase (ALP) for ≥6 months
2. Positive anti-mitochondrial antibody (AMA) (titre ≥1:40) or PBC-specific antinuclear antibodies (anti-sp100, anti-gp210)
3. Liver biopsy showing histology consistent with PBC (florid duct lesion, bile duct destruction, ductopenia)

In most cases, diagnosis is made on criteria 1 and 2 (cholestatic LFTs + AMA positivity) without the need for liver biopsy. Liver biopsy is reserved for AMA-negative cases, suspected overlap syndrome, or atypical features.

Q3: How do you differentiate PBC from Primary Sclerosing Cholangitis (PSC)?

Model Answer:

Key differentiator: MRCP is normal in PBC but shows beaded bile ducts in PSC.

Q4: What is the first-line treatment for PBC, and what is the mechanism of action?

Model Answer: The first-line treatment for PBC is Ursodeoxycholic Acid (UDCA) at a dose of 13-15 mg/kg/day.

Mechanism of action:

1. Replaces toxic hydrophobic bile acids (chenodeoxycholic acid, deoxycholic acid) with non-toxic hydrophilic UDCA
2. Choleretic effect: Promotes bile flow and reduces cholestasis
3. Cytoprotective: Reduces hepatocyte apoptosis induced by toxic bile acids
4. Immunomodulatory: Reduces aberrant MHC class II expression on biliary epithelial cells, dampening immune attack
5. Antioxidant and anti-inflammatory properties

Efficacy:

• Improves liver biochemistry in 60-70% of patients
• Delays histological progression to cirrhosis
• Improves transplant-free survival, especially if started in early disease
• Delays onset of varices in patients with advanced fibrosis

All patients with confirmed PBC should be started on UDCA unless there are specific contraindications.

Q5: How do you assess response to UDCA therapy, and what do you do if there is inadequate response?

Model Answer:

Assessing Response (at 12 months of UDCA therapy):

The most commonly used criterion is the Paris-2 criteria, which defines adequate response as:

• ALP < 1.5× ULN
• AST < 1.5× ULN
• Bilirubin ≤17 μmol/L (1 mg/dL)

Patients meeting these criteria at 12 months have significantly improved transplant-free survival compared to non-responders.

Alternatively, the Toronto criteria (ALP < 1.67× ULN) can be used.

If Inadequate Response:

Approximately 30-40% of patients are incomplete responders to UDCA and require second-line therapy:

1. Obeticholic Acid (OCA):

   • Farnesoid X receptor (FXR) agonist
   • Dose: 5-10 mg daily (add to UDCA)
   • FDA/EMA approved second-line therapy
   • Contraindicated in decompensated cirrhosis (Child-Pugh B/C)
   • Side effect: Pruritus (dose-limiting in some patients)

2. Bezafibrate (off-label, especially in Europe):

   • PPAR-α agonist
   • Dose: 400 mg daily
   • Improves ALP and also pruritus
   • Generally well tolerated

3. Seladelpar (recently approved):

   • Selective PPAR-δ agonist
   • Improves ALP and pruritus
   • Emerging second-line option

If still inadequate or decompensated cirrhosis develops: Liver transplant evaluation.

Q6: What is PBC-AIH overlap syndrome, and how is it diagnosed and managed?

Model Answer:

PBC-AIH overlap syndrome is a condition where patients have features of both Primary Biliary Cholangitis and Autoimmune Hepatitis simultaneously. It occurs in approximately 5-10% of patients.

Diagnosis (Paris Criteria):

Requires meeting criteria for both PBC and AIH:

PBC criteria (≥2 of):

1. ALP ≥2× ULN or GGT ≥5× ULN
2. AMA positive
3. Liver biopsy with florid duct lesion

AIH criteria (≥2 of):

1. ALT ≥5× ULN
2. IgG ≥2× ULN or ASMA positive
3. Liver biopsy with moderate/severe interface hepatitis

Key features suggesting overlap:

• Mixed LFT pattern: Elevated ALP (cholestatic) and elevated ALT (hepatitic)
• Dual seropositivity: AMA + ANA/ASMA
• Elevated IgG and IgM

Management:

Combination therapy is required:

• UDCA 13-15 mg/kg/day (for PBC component)
• Immunosuppression (for AIH component):
  • Prednisolone (starting 30-40 mg daily, taper according to response)
  • ± Azathioprine (50-100 mg daily) as steroid-sparing agent

Prognosis: Overlap syndrome may have a more aggressive course than either condition alone. Close monitoring and combination therapy are essential.

Q7: What is the single most important prognostic marker in PBC?

Model Answer:

The serum bilirubin level is the single most important prognostic marker in PBC.

Why?

• Rising bilirubin indicates progressive cholestasis and failing hepatic function, which correlates strongly with poor outcomes.
• Persistent bilirubin 100 μmol/L (6 mg/dL) is associated with a median survival of 2-3 years without liver transplantation.
• Bilirubin is the strongest component of prognostic models (Mayo Risk Score, GLOBE score, UK-PBC score).

Clinical Significance:

• Normal bilirubin on UDCA therapy: Excellent prognosis, near-normal life expectancy
• Rising bilirubin despite UDCA: Poor prognosis, mandates liver transplant evaluation

Other important prognostic factors include:

• UDCA biochemical response (Paris-2 criteria)
• Stage of fibrosis (early vs. cirrhosis)
• Albumin level (synthetic function)
• Presence of decompensation (ascites, varices, encephalopathy)

Q8: Describe the stepwise management of pruritus in PBC.

Model Answer:

Pruritus in PBC can be profoundly debilitating and requires a stepwise approach:

1st Line: Cholestyramine

• Dose: 4-16 g/day in divided doses
• Mechanism: Bile acid sequestrant (binds bile acids in gut)
• Efficacy: Effective in 50-70%
• Important: Take 2-4 hours away from other medications (including UDCA) as it binds drugs
• Side effects: Constipation, bloating, unpalatable

2nd Line: Rifampicin

• Dose: 150-300 mg twice daily
• Mechanism: Enzyme inducer (increases bile acid metabolism)
• Efficacy: Very effective (50-80%)
• Caution: Hepatotoxicity risk – monitor LFTs closely
• Side effects: Drug interactions, orange discoloration of urine/tears

3rd Line: Naltrexone

• Dose: 12.5-50 mg daily (start low, titrate)
• Mechanism: Opioid antagonist (modulates endogenous opioid pathways)
• Side effects: Opioid withdrawal-like symptoms initially, nausea
• Contraindication: Cannot use if on opioid analgesics

4th Line: Sertraline

• Dose: 75-100 mg daily
• Mechanism: SSRI (central neurotransmitter modulation)
• Efficacy: Some evidence in small trials
• Side effects: Standard SSRI side effects

Alternative: Bezafibrate

• Can be used as second-line PBC therapy in UDCA non-responders
• Dual benefit: Improves biochemistry and pruritus

Refractory Cases:

• Plasmapheresis/MARS (Molecular Adsorbent Recirculating System): Temporary relief, bridge to transplant
• Liver Transplantation: Definitive cure for intractable pruritus (rare indication)

Symptomatic Measures:

• Cool environment, emollients, avoid irritants, short nails

Q9: What are the indications for liver transplantation in PBC, and what are the outcomes?

Model Answer:

Indications for Liver Transplantation:

1. Decompensated cirrhosis:

   • Ascites (refractory to medical therapy)
   • Variceal haemorrhage
   • Hepatic encephalopathy
   • Hepatorenal syndrome
   • Spontaneous bacterial peritonitis

2. Progressive liver dysfunction:

   • Rising bilirubin despite therapy (especially 100 μmol/L)
   • MELD score ≥15
   • Declining synthetic function (low albumin, prolonged INR)

3. Hepatocellular carcinoma (within Milan criteria)

4. Intractable pruritus (rare indication):

   • Severely affecting quality of life
   • Refractory to all medical therapies
   • Usually only if concurrent liver dysfunction

Timing:

• Refer early (MELD 12-15) for evaluation and listing before decompensation
• Rising bilirubin is a key trigger for transplant evaluation

Outcomes:

PBC has excellent transplant outcomes, among the best of all indications:

Recurrent PBC:

• Occurs in 15-30% of patients at 10 years post-transplant
• Diagnosis: AMA remains positive, histology shows florid duct lesion
• Usually mild and slowly progressive
• UDCA is recommended post-transplant (may reduce recurrence risk)

Post-Transplant Management:

• Standard immunosuppression (tacrolimus, mycophenolate ± steroids)
• Continue UDCA
• Monitor for recurrence (LFTs, AMA, biopsy if indicated)

OSCE/Clinical Examination Scenarios

Scenario 1: History Taking

You are asked to take a history from a 52-year-old woman referred by her GP with abnormal liver function tests showing elevated ALP.

Key Points to Cover:

• Symptoms: Fatigue, pruritus (onset, severity, impact on sleep/QoL), jaundice, abdominal discomfort
• Associated autoimmune symptoms: Dry eyes, dry mouth (Sjögren's), joint pains (RA), Raynaud's, thyroid symptoms
• Risk factors for other liver diseases: Alcohol intake, medications, travel, viral hepatitis risk, family history of liver disease
• Family history: Autoimmune diseases, PBC
• Impact on life: Work, sleep, mood
• Examination findings: Jaundice, scratch marks, xanthelasma
• Explain next steps: Blood tests (AMA, LFTs), ultrasound, possible specialist referral

Scenario 2: Explaining Diagnosis to Patient

A 55-year-old woman has been diagnosed with PBC. Explain the diagnosis and management plan.

Key Points:

• What is PBC: Autoimmune condition where immune system attacks small bile ducts in liver, causing bile build-up and inflammation
• Not your fault: Not caused by alcohol or anything you did
• Symptoms: Tiredness and itching are common; many people have no symptoms initially
• Treatment: Medication called UDCA (ursodeoxycholic acid) taken daily; slows disease, improves outcomes
• Prognosis: With treatment, most people live a normal or near-normal lifespan
• Monitoring: Regular blood tests to check how well treatment is working
• Lifestyle: Avoid smoking, limit alcohol, healthy diet
• Associated conditions: May have dry eyes/mouth, thyroid problems – we will screen for these
• Opportunity for questions

---

14. References

Primary Sources

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-172. PMID: 28427765. DOI: 10.1016/j.jhep.2017.03.022

2. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419. PMID: 30070375. DOI: 10.1002/hep.30145

3. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Anti-mitochondrial antibody detection in primary biliary cholangitis: Comparative evaluation of different assays. J Immunol Methods. 2022;507:113288. PMID: 36453746. DOI: 10.1016/j.jim.2022.113288

4. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123(4):1044-1051. PMID: 12360466. DOI: 10.1053/gast.2002.36027

5. Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2021;27(1):1-21. PMID: 33264835. DOI: 10.3350/cmh.2020.0028

6. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181-1188. PMID: 22245904. DOI: 10.1016/j.jhep.2011.10.025

7. Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis. 2014;34(3):352-360. PMID: 25057957. DOI: 10.1055/s-0034-1383733

8. Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. 2018;378(23):2171-2181. PMID: 29874527. DOI: 10.1056/NEJMoa1714519

9. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. J Hepatol. 2015;63(5):1285-1287. PMID: 26216533. DOI: 10.1016/j.jhep.2015.06.031

10. Hegade VS, Kendrick SF, Jones DEJ. Fatigue and pruritus in primary biliary cholangitis. Clin Liver Dis. 2022;19(3):102-105. PMID: 36270726. DOI: 10.1002/cld.1194

11. Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28(2):296-301. PMID: 9695992. DOI: 10.1002/hep.510280203

12. Webb GJ, Hirschfield GM. Using clinical and genetic data to understand primary biliary cholangitis. Clin Liver Dis. 2018;11(2):37-41. PMID: 30992807. DOI: 10.1002/cld.709

13. Lleo A, Leung PSC, Hirschfield GM, Gershwin ME. The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. Semin Liver Dis. 2020;40(1):34-48. PMID: 31819247. DOI: 10.1055/s-0039-1697617

14. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45(1):118-127. PMID: 17187436. DOI: 10.1002/hep.21472

15. Rudić JS, Poropat G, Krstelj A, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551. PMID: 23235576. DOI: 10.1002/14651858.CD000551.pub3

16. Nevens F, Andreone P, Mazzella G, et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016;375(7):631-643. PMID: 27532829. DOI: 10.1056/NEJMoa1509840

17. Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57(5):1931-1941. PMID: 23184571. DOI: 10.1002/hep.26018

18. Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2(10):716-726. PMID: 28851689. DOI: 10.1016/S2468-1253(17)30246-7

19. Carbone M, Neuberger JM. Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol. 2011;35(6-7):446-454. PMID: 21632313. DOI: 10.1016/j.clinre.2011.02.007

20. Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568-1594. PMID: 29593060. DOI: 10.1136/gutjnl-2017-315259

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to current guidelines.